(Q51173696)

English

Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

scientific article published in January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. (English)

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George J Kontoghiorghes

2

object named as

George J Kontoghiorghes

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

author name string

Annita Kolnagou

1

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

publication date

1 January 2006

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

30

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

2

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

239-249

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Chelation therapy in beta-thalassemia: an optimistic update

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Hepatic iron concentration and total body iron stores in thalassemia major.

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Effects of ICL670 (deferasirox) on cardiac iron concentrations

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Development of tridentate iron chelators: from desferrithiocin to ICL670.

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1080%2F03630260600642567

21 January 2018

Identifiers

10.1080/03630260600642567

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

1 reference

Europe PubMed Central

31 March 2018

http://europepmc.org/abstract/MED/16798649

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51173696&oldid=1584425447"